Pricing Log in Create free account
Saturday 17 October 2026 Export ATNM’s income statement to Excel — free account

Actinium Pharmaceuticals, Inc.

ATNM Healthcare Biotechnology

Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023. In the quarter to June 2026, revenue grew 77,677.8%, EPS grew 504.6% and free cash flow fell 4.91%, each against the same quarter a year earlier.

1.13 0.07 +6.60%
Market cap
$33.3M
P/E
3.1×
Fwd P/E
−1.3×
Dividend yield
—
F-score
n/a
Altman Z
−11.85
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 1.62%

Capital & Financial Ratios $m

Market Cap 33.32
Revenue 35.14
Net Income 11.31
Free Cash Flow (23.25)
Net Debt (36.47)
Current Ratio 4.08 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 3.14
Fwd P/E (1.29) (negative: loss-making)
P/S ratio 1.01
P/B ratio 1.17
Past 5Y EPS Growth —
This Y EPS Growth 116.21% (at or above 15%: strong)
Next Y EPS Growth (420.75%) (below 0%: weak)
Next Y revenue growth 19,344.44% (at or above 10%: strong)
Next 5Y EPS Growth 20.23% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.0×, against a ten-year median of 27.8×; over the ten years it ranged from −65.6× in 2026 to 217× in 2022.
P/S against its own 10 years 4.82%
10-year low 10-year high
P/B against its own 10 years 4.50%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 77 73 48 36
Receivables — — — —
Inventory — — — —
Other — — — —
78 75 49 38
2023 2024 2025 Q'26
Payables 8 8 7 9
ST’ Debt — — — —
Other — — — —
8 8 8 9

Compound Annual Growth %

10y 5y 3y
Sales — — (57.15%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (9.80%) (33.74%) (50.97%)

Revenue $m

Mar Jun Sep Dec Year
’26 — 35 — — —
’25 — — 0 — 0
’23 — — — — 0
’22 1 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (5) — — —
’25 (8) (5) (6) (5) (25)
’24 (7) (8) (12) (6) (33)
’23 (15) (14) (11) (7) (47)
’22 (6) 28 (6) (8) 9
’21 (6) (5) (6) (5) (21)
’20 (6) (5) (5) (6) (22)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (6) — — —
’25 (8) (5) (6) (5) (25)
’24 (7) (8) (12) (6) (33)
’23 (15) (14) (11) (7) (47)
’22 (6) 28 (6) (8) 8
’21 (6) (5) (6) (5) (21)
’20 (6) (5) (5) (7) (22)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.18) 0.89 — — —
’25 (0.51) (0.22) (0.16) (0.19) (1.09)
’24 (0.31) (0.38) (0.37) (0.21) (1.27)
’23 (0.43) (0.58) (0.49) (0.33) (1.83)
’22 (0.23) (0.33) (0.38) (0.42) (1.37)
’21 (0.29) (0.25) (0.30) (0.37) (1.20)
’20 (0.98) (0.41) (0.36) (0.09) (1.83)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 25.80 16.17 9.96 5.70 4.71 5.70 4.41 4.00 1.10 1.03

Analyst estimates 2026–2028

Powerpack
High 105.00 51.60 25.95 21.27 19.47 10.30 15.12 14.70 10.24 2.41
People
People Employees 23 25 30 25 32 32 49 49 37 25
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.04 0.02 0.00 0.00 0.00
Income, $m
Income, $m Revenue — — — — — 1 1 0 — 0
Gross margin, % 0.00 0.00 0.00 0.00 0.00 100.00 100.00 100.00 — 100.00
EBT (24) (27) (24) (22) (22) (25) (33) (49) (38) (34)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 (2,165.56) (3,205.53) (60,269.14) 0.00 (37,652.22)
Net income (24) (27) (24) (22) (22) (25) (33) (49) (38) (34)
Depreciation 0 0 0 0 0 1 1 1 1 1
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.06 0.04 0.00 0.00 0.00
Earnings (15.01) (12.01) (6.61) (4.33) (1.83) (1.17) (1.37) (1.83) (1.27) (1.09)
Cash flow (12.88) (9.70) (5.83) (4.31) (1.78) (1.01) 0.36 (1.78) (1.10) (0.79)
Capex (0.04) (0.01) (0.03) (0.01) (0.02) (0.01) (0.02) (0.01) 0.00 0.00
Free cash flow (12.92) (9.71) (5.85) (4.33) (1.80) (1.02) 0.34 (1.78) (1.10) (0.79)
Book value 11.16 6.15 2.50 1.13 5.05 3.58 2.75 1.37 1.09 0.25
Shares, m 2 2 4 5 12 21 24 27 30 31
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 — 0.00
P/S — — — — — 108.06 234.86 137.41 — 235.70
P/B — — — — — 1.68 3.64 3.89 — 5.42
EV/Sales — — — — — 39.64 130.76 62.99 — (30.94)
EV/FCF — — — — — (2.16) 16.27 (1.37) — 0.23
Cash, $m
Cash, $m Operating cash flow (21) (22) (21) (21) (22) (21) 9 (47) (33) (25)
Capex 0 0 0 0 0 0 0 0 0 0
Free cash flow (21) (22) (21) (22) (22) (21) 8 (47) (33) (25)
Balance, $m
Balance, $m Working capital 18 13 8 5 60 73 100 70 66 41
Total debt — — 0 0 0 0 2 0 0 —
Net debt (21) (17) (14) (9) (64) (78) (107) (77) (73) (48)
Shareholders’ equity 18 14 9 6 61 74 66 36 33 8
Returns, %
Returns, % ROA (99.04) (130.19) (142.38) (164.92) (56.92) (33.76) (33.94) (49.91) (48.30) (52.67)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (121.66) (167.94) (210.41) (302.99) (66.35) (36.74) (47.16) (94.92) (110.63) (166.96)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Actinium Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LIANY LianBio Sponsored ADR $34.2M 0.0× — — n/m +1,107.59% (above 0%: growing) 0.00% 0.00% Compare
CRVO CervoMed Inc. $34.0M — (loss-making) — (loss-making) −99.60% (below 0%: shrinking) n/m −6.20% (below 0%: shrinking) 100.00% 0.00% Compare
IRLA Quince Therapeutics, Inc. $33.8M — (loss-making) — — n/m −63.65% (below 0%: shrinking) 0.00% 0.00% Compare
ALGS Aligos Therapeutics, Inc. $33.7M — (loss-making) — (loss-making) +2,778.55% (above 0%: growing) n/m −59.81% (below 0%: shrinking) 100.00% (6.80%) Compare
ATNM Actinium Pharmaceuticals, Inc. $33.3M 3.1× — (loss-making) +77,677.78% (above 0%: growing) n/m −4.91% (below 0%: shrinking) 100.00% 78.76%
BCTX BRIACELL THERAP $32.8M 1.5× — — n/m +0.21% (above 0%: growing) 0.00% 0.00% Compare
GNTA Genenta Science S.p.A. Unsponsored ADR $32.3M — — — — +35.94% (above 0%: growing) 0.00% — Compare
MGX Metagenomi Therapeutics, Inc. $31.9M — (loss-making) — (loss-making) −103.02% (below 0%: shrinking) n/m +7.98% (above 0%: growing) 100.00% 11,195.72% Compare
GRDX GridAI Technologies Corp. $31.8M — (loss-making) — — n/m −2,640.98% (below 0%: shrinking) (42.49%) (15,258.21%) Compare
Median of peers $33.2M — — −99.60% — −2.99% 0.00% 0.00%

All 614 Biotechnology stocks →

Actinium Pharmaceuticals, Inc. (ATNM) key facts

  • Concern: Actinium Pharmaceuticals, Inc. reported a net loss of $33.9 million, or a loss of $1.09 per share, for fiscal 2025.
  • Strength: Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023.
  • Actinium Pharmaceuticals, Inc. (ATNM) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
  • As of October 16, 2026, ATNM traded at $1.13, a market capitalization of $33.3 million.
  • At that price the stock trades at 3.1× trailing-twelve-month earnings and 1.0× sales.
  • Return on equity was −167.0% and debt-to-equity 0.00.
  • Its Altman Z-score is −11.85 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Actinium Pharmaceuticals, Inc. (ATNM) Latest News

11 Dec

Impact 5 ·
stockrow.com/ATNM · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com